Galecto | Damora Therapeutics

Damora Therapeutics is an innovative clinical-stage biotechnology company that traces its foundational beginnings to 2011 when it was established under the name Galecto. Initially focused on developing galectin-3 inhibitors for the treatment of fibrosis and cancer, the company operated under the Galecto brand for over a decade before executing a significant strategic pivot. In late 2025, the company acquired the legacy Damora entity to shift its scientific focus toward the development of disease-modifying biologics specifically designed for patients suffering from high-need genetic blood disorders.

The company operates within the global biotechnology and life sciences sector, targeting a market comprised of healthcare providers and patients with rare hematologic malignancies. Its business model is centered on a research-heavy approach where value is generated through the progression of novel drug candidates through complex clinical trial phases. As a clinical-stage entity, Damora Therapeutics relies on strategic private placements and public equity offerings to sustain its operations while it works toward the eventual regulatory approval and commercialization of its therapeutic pipeline.

The primary technological focus of the company is the development of DMR-001, a long-acting antibody engineered to target mutant calreticulin (mutCALR), which is a key driver in myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. This approach differentiates the company from traditional symptomatic treatments by attempting to address the underlying genetic cause of the disease. By combining its historical expertise in biological pathways with newly acquired assets in antibody engineering, Damora Therapeutics is positioned to deliver targeted therapies that offer broad mutation coverage and improved patient convenience.

Keywords: biotechnology, hematology, oncology, mutant calreticulin, biologics, drug discovery, clinical-stage, Galecto, blood disorders, myeloproliferative neoplasms, antibody engineering, rare diseases.